Shah S D, Clutter W E, Cryer P E
J Lab Clin Med. 1985 Dec;106(6):624-9.
In plasma from normal humans (n = 9, 35 samples) and from patients with diabetes mellitus (n = 12, 24 samples) single-isotope derivative (radioenzymatic) plasma norepinephrine and epinephrine concentrations calculated from external standard curves constructed in a normal plasma pool were identical to those calculated from internal standards added to an aliquot of each plasma sample. In plasma from patients with end-stage renal failure receiving long-term dialysis (n = 34, 109 samples), competitive catechol-O-methyltransferase (COMT) inhibitory activity resulted in a systematic error when external standards in a normal plasma pool were used, as reported previously; values so calculated averaged 21% (+/- 12%, SD) lower than those calculated from internal standards. However, when external standard curves were constructed in plasma from a given patient with renal failure and used to calculate that patient's values, or in a renal failure plasma pool and used to calculate all renal failure values, norepinephrine and epinephrine concentrations were not significantly different from those calculated from internal standards. We conclude: (1) External standard curves constructed in plasma from a given patient with renal failure can be used to measure norepinephrine and epinephrine in plasma from that patient; further, external standards in a renal failure plasma pool can be used for assays in patients with end-stage renal failure receiving long-term dialysis. (2) Major COMT inhibitory activity is not present commonly if samples from patients with renal failure are excluded. Thus, it would appear that external standard curves constructed in normal plasma can be used to measure norepinephrine and epinephrine precisely in samples from persons who do not have renal failure.(ABSTRACT TRUNCATED AT 250 WORDS)
在正常人类(n = 9,35份样本)和糖尿病患者(n = 12,24份样本)的血浆中,根据在正常血浆池构建的外标曲线计算出的单同位素衍生物(放射酶法)血浆去甲肾上腺素和肾上腺素浓度,与向每份血浆样本的一份等分试样中加入内标后计算出的浓度相同。如先前报道,在接受长期透析的终末期肾衰竭患者(n = 34,109份样本)的血浆中,当使用正常血浆池中的外标时,竞争性儿茶酚-O-甲基转移酶(COMT)抑制活性会导致系统误差;如此计算出的值平均比根据内标计算出的值低21%(±12%,标准差)。然而,当在给定肾衰竭患者的血浆中构建外标曲线并用于计算该患者的值,或在肾衰竭血浆池中构建外标曲线并用于计算所有肾衰竭患者的值时,去甲肾上腺素和肾上腺素浓度与根据内标计算出的值无显著差异。我们得出结论:(1)在给定肾衰竭患者的血浆中构建的外标曲线可用于测量该患者血浆中的去甲肾上腺素和肾上腺素;此外,肾衰竭血浆池中的外标可用于接受长期透析的终末期肾衰竭患者的检测。(2)如果排除肾衰竭患者的样本,通常不存在主要的COMT抑制活性。因此,似乎在正常血浆中构建的外标曲线可用于精确测量非肾衰竭患者样本中的去甲肾上腺素和肾上腺素。(摘要截断于250字)